Oncotelic Therapeutics Inc · OTC:OTLC
Oncotelic Therapeutics — Mateon Therapeutics — Corporate Update (April 2020)
15 slides from Oncotelic Therapeutics's corporate update, Apr 20, 2020
Slide 1: Immediate Therapeutic Response to COVID-19: OT-101/Trabedersen
MATEON Building the next generation biotech focusing on speed and efficiency IMMEDIATE THERAPEUTIC RESPONSE TO COVID-19: OT-101/TRABEDERSEN APRIL 9, 2020 Sl ceon com ONCOTELIC WWW_ONCOTELIC._COM
Slide 2: OT-101 — Summary
OT-101 — SUMMARY Potential to Treat COVID-19 at different Anti-Viral Replication Activity eee * Highly potent: * Inhibition of viral © SARS-CoV-1: ECag replication of 7.6 pg/mL with ¢ Suppression of a selective index virus-induced lung (SI) of >130 inflammation and * SARS-CoV-2: EC. pneumonia. of 2.
Slide 3: Mateon's Lead Candidate: OT-101 (Trabedersen)
MATEON’S LEAD CANDIDATE: OT-101 (TRABEDERSEN) Trabedersen (OT-101) is a single-stranded phosphorothioate antisense oligodeoxynucleotide (18-mer) designed to specifically target the human TGF-B2 messenger RNA OT-101 has the potential to hit COVID-19 at 3 critical junctures mediated by TGF-B: 1) virus
Slide 4: Technology Readiness Level of OT-101
MATEON TECHNOLOGY READINESS LEVEL OF OT-101 Level Descr' n TRL7 ¥ Assays: Validate assays for manufacturing quality control & immunogenicity v Manufacturing: - Scale-up and validate GMP manufacturing process at a scale compatible with USG requirements. - Begin stability studies of the GMP product in
Slide 5: OT-101: Drug Product - TGF-B2 Antisense
OT-101: DRUG PRODUCT- TGF-B2 ANTISENSE. Ready for oncology registration trials--Over 200 patients treated across 6 clinical trials Orphan designation granted for three tumor indications in US & EU/ Rare Pediatric Designation for DIPG. Manufacturing process optimized and scaled up Sufficient drug to
Slide 6: Rationale for OT-101: Role of TGF-B in Virus Replication
MATEON RATIONALE FOR OT-101: ROLE OF TGF-B IN VIRUS REPLICATION Several viruses trigger cell cycle dysregulation to support their replication in cells. Anumber of these viruses employ TGF-8 in affecting the host cell cycle progression. Respiratory syncytial virus (RSV) induces TGF-B expression resul
Slide 7: OT-101 Inhibits SARS-CoV-1 and SARS-CoV-2 In Vitro
eco! OT-101 INHIBITS SARS-COV-1 AND SARS-COV-2 IN VITRO * Incollaboration with Dr. Brett Hurst at Utah State University, part of the NIAID Antiviral Testing Consortium * Invitro antiviral activity against SARS-CoV-1 and SARS-CoV-2 in Vero 76 cells. Compound Virus EC., Ce. Sy] OT-101 SARS-CoV-1 (Urba
Slide 8: Rationale for OT-101: Role of TGFB in CoV-Induced ARDS
MATEON RATIONALE FOR OT-101: ROLE OF TGFB IN CoV-INDUCED ARDS TGF-f is an important pro-inflammatory cytokine in the pathophysiology of acute lung injury and ARDS that contributes to both increased permeability and failed fluid reabsorption in lungs leading to persistent and severe pulmonary edema.
Slide 9: Favorable PK: Lung Accumulation and Stable Plasma Concentration
FAVORABLE PK: LUNG ACCUMULATION AND STABLE PLASMA CONCENTRATION In both humans an rats, the distribution of trabedersen to tissues was not only rapid, but also extensive, with deep tissue penetration as demonstrated by the finding that the volume of the peripheral compartment far exceeded the total
Slide 10: Prior Clinical Experience in Gliomas, Pancreas and Melanoma
PRIOR CLINICAL EXPERIENCE IN GLIOMAS, PANCREAS AND MELANOMA CANCERS * 6 Clinical Trials with more than 200 pts / 189 pts treated with OT-101 ° Robust Efficacy against multiple TGF-B expressing tumors PROMISING c PANCREAS CLINICAL y) | os ; : GLIOMAS ACTIVITY a - MELANOMA Trial____[Trabedersen tion M
Slide 11: Favorable Safety Profile - Low Toxicity
FAVORABLE SAFETY PROFILE- LOW TOXICITY ° Low Related Adverse Events — P001 * Pancreatic Cancer/ Melanoma/ Colorectal Cancer/N =total number of patients; No. = number; TEAE = treatment- emergent adverse event; FAS = full analysis set Preferred Term aiceal (N=61) 6 (9.8)/21 | 1 (1.6)/1 [Nausea CS 1(1.
Slide 12: Proposed Phase IIA/III Clinical Trial Design for COVID-19
MATEON PROPOSED PHASE IIA/III CLINICAL TRIAL DESIGN FOR COVID-19 OT-101 Part 1 Dose: 150 mg/m? on day 1, 100 mg/m? on days 2-7 Intravenous infusion + COVID-19 Standard of Care Patients : N=7 with Hypoxemic OT-101 . _ 2 2 ie Respiratory Dose: 150 mg/m: on day 1, 100 mg/m? on days 2-7 Intravenous infu
Slide 13: OT-101 — Summary
OT-101 — SUMMARY Potential to Treat COVID-19 at different Anti-Viral Replication Activity eee * Highly potent: * Inhibition of viral © SARS-CoV-1: ECag replication of 7.6 pg/mL with ¢ Suppression of a selective index virus-induced lung (SI) of >130 inflammation and * SARS-CoV-2: EC. pneumonia. of 2.
Slide 14: Proven and Experienced Response Team
PROVEN AND EXPERIENCED RESPONSE TEAM MATEON Fatih Uckun MD PhD Dr. Seymour Fein MD Cyril Empig PhD Vuong Trieu PhD Steven King * Clinical Strategy Lead, COVID-19 Task Force, Worldwide Clinical Trials * More than 20 years of experience in treatment of viral, fungal, and bacterial infections, septic s
Slide 15: Thank You
Thank You Vuong Trieu/ vtrieu@oncotelic.com Cyril Empig/ cempig@oncotelic.com